The primary objective of the translational core is to provide patient access and quality data collection. In order to constuct clinical cohorts for translational investigations, we have chosen to use two populations enriched for pulmonary arterial hypertension - COPD and HIV. Both COPD and HIV+ patients develop pulmonary hypertension at a rate significantly greater than the general population. Morbidity and mortality are also greatly increased in dually affected persons. Through our ongoing clinical studies, we have access to well-charaterized research subjects who are at risk for pulmonary arterial hypertension (PAH). Available cohorts include an Emphysema Registry, Lung Tissue Research Consortium participante, smokers enrolled in our COPD Specialized Center of Clinically Oriented Research grant, and HIV-infected and HIV-uninfected controls from local and multicenter trials. Together, these populations comprise over 2000 research subjects. The human core will support goals of all projects by identifying and characterizing populations to be used for evaluating mechanistic pathways in various PAH sub-phenotypes and by establishing clinical cohorts in whom to test novel therapeutic agents. The core will provide expertise in population screening, use of biomarkers, genomics, computed tomography, Doppler-echocardiography, and right heart catheterization in order to identify and characterize the subphenotypes of PAH in COPD and HIV. The core will supply imaging, catheterization, biobanking, and bioinformatics and statistical support for all Projects. Importantly, the clinical core will synergize with the pre-clinical core to translate findings from bench-to-bedside. The core will meet its goals by addressing the following Specific Aims:
Specific Aim 1 : To establish a cohort exhibiting the PAH phenotype from our diverse patient populations in order to support the Research Projects in translational investigations and to assess utility of plasma NT-proBNP as a biomarker of PAH.
Specific Aim 2 : To assist program investigators in testing novel therapeutic interventions in pulmonary arterial hypertension.
Specific Aim 3. To establish a biorepository for mechanistic studies of PAH sub-phenotypes.

Public Health Relevance

Both COPD and HIV-infected patients are disproportionally affected by pulmonary arterial hypertension (PAH). Little work has been done to understand these particular phenotypes of PAH. Establishing a cohort in whom to explore mechanisms of disease pathogenesis and for testing of novel therapeutics would have a large public health impact for these populations and others who suffer from PAH.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
1P01HL103455-01
Application #
7982562
Study Section
Special Emphasis Panel (ZHL1-CSR-A (M1))
Project Start
2011-06-01
Project End
2016-04-30
Budget Start
2011-06-01
Budget End
2012-04-30
Support Year
1
Fiscal Year
2011
Total Cost
$483,404
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Kim-Campbell, Nahmah; Gretchen, Catherine; Callaway, Clifton et al. (2017) Cell-Free Plasma Hemoglobin and Male Gender Are Risk Factors for Acute Kidney Injury in Low Risk Children Undergoing Cardiopulmonary Bypass. Crit Care Med 45:e1123-e1130
Meng, Qingqing; Lai, Yen-Chun; Kelly, Neil J et al. (2017) Development of a Mouse Model of Metabolic Syndrome, Pulmonary Hypertension, and Heart Failure with Preserved Ejection Fraction. Am J Respir Cell Mol Biol 56:497-505
Meijles, Daniel N; Sahoo, Sanghamitra; Al Ghouleh, Imad et al. (2017) The matricellular protein TSP1 promotes human and mouse endothelial cell senescence through CD47 and Nox1. Sci Signal 10:
Hughan, Kara S; Wendell, Stacy Gelhaus; Delmastro-Greenwood, Meghan et al. (2017) Conjugated Linoleic Acid Modulates Clinical Responses to Oral Nitrite and Nitrate. Hypertension :
Gladwin, Mark T (2017) Translational Advances in the Field of Pulmonary Hypertension Bench to Bedside: How Fundamental Discoveries in Science Are Advancing Our Understanding and Therapy of Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 195:1-3
Fazzari, Marco; Khoo, Nicholas K H; Woodcock, Steven R et al. (2017) Nitro-fatty acid pharmacokinetics in the adipose tissue compartment. J Lipid Res 58:375-385
Grzegorzewska, Agnieszka P; Seta, Francesca; Han, Rong et al. (2017) Dimethyl Fumarate ameliorates pulmonary arterial hypertension and lung fibrosis by targeting multiple pathways. Sci Rep 7:41605
Kelly, Neil J; Radder, Josiah E; Baust, Jeffrey J et al. (2017) Mouse Genome-Wide Association Study of Preclinical Group II Pulmonary Hypertension Identifies Epidermal Growth Factor Receptor. Am J Respir Cell Mol Biol 56:488-496
Radder, Josiah E; Zhang, Yingze; Gregory, Alyssa D et al. (2017) Extreme Trait Whole-Genome Sequencing Identifies PTPRO as a Novel Candidate Gene in Emphysema with Severe Airflow Obstruction. Am J Respir Crit Care Med 196:159-171
Pena, Andressa; Kobir, Ahasanul; Goncharov, Dmitry et al. (2017) Pharmacological Inhibition of mTOR Kinase Reverses Right Ventricle Remodeling and Improves Right Ventricle Structure and Function in Rats. Am J Respir Cell Mol Biol 57:615-625

Showing the most recent 10 out of 162 publications